CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in March

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 9,000,000 shares, a growth of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the company’s shares are short sold. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is presently 5.0 days.

CytomX Therapeutics Trading Up 1.9 %

CytomX Therapeutics stock traded up $0.01 during mid-day trading on Friday, hitting $0.63. The company had a trading volume of 831,077 shares, compared to its average volume of 2,635,887. CytomX Therapeutics has a 12 month low of $0.56 and a 12 month high of $5.85. The stock’s 50 day moving average price is $0.75 and its two-hundred day moving average price is $0.97. The company has a market capitalization of $50.32 million, a PE ratio of 3.70 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.45. The company had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. Equities research analysts anticipate that CytomX Therapeutics will post -0.05 EPS for the current year.

Wall Street Analyst Weigh In

CTMX has been the topic of several research reports. StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, March 10th. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, Wedbush restated an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.02.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Miller Financial Services LLC bought a new stake in CytomX Therapeutics in the 4th quarter worth about $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the 4th quarter valued at about $31,000. Algert Global LLC purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $35,000. Velan Capital Investment Management LP bought a new position in CytomX Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Aspire Growth Partners LLC purchased a new stake in CytomX Therapeutics in the fourth quarter worth approximately $42,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.